CureVac NV
1CVAC
Company Profile
Business description
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Contact
Friedrich-Miescher-Strasse 15
TubingenBW72076
DEUT: +49 707198830
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,088
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,175.10 | 49.90 | 0.61% |
| CAC 40 | 7,554.27 | 51.49 | 0.69% |
| DAX 40 | 22,243.06 | 178.55 | 0.81% |
| Dow JONES (US) | 40,049.99 | 43.41 | -0.11% |
| FTSE 100 | 8,419.85 | 12.41 | 0.15% |
| HKSE | 21,980.74 | 70.98 | 0.32% |
| NASDAQ | 17,176.31 | 10.26 | 0.06% |
| Nikkei 225 | 35,705.74 | 666.59 | 1.90% |
| NZX 50 Index | 12,017.84 | 61.37 | 0.51% |
| S&P 500 | 5,485.56 | 0.79 | 0.01% |
| S&P/ASX 200 | 7,968.20 | 47.70 | 0.60% |
| SSE Composite Index | 3,295.06 | 2.23 | -0.07% |